TNBC vs ER/PR+ vs HER2+ Subtype Survival in Stage IV Metastatic Breast Cancer

  • Late Stage patients with overexpression of either ER, PR and/or HER2 overexpression had higher survival rates.
  • Late Stage patients with overexpression of both ER/PR and HER2 had the highest survival rates.
  • Patients without ER/PR or HER2 (Triple Negative) had the lowest survival rate.
Estimated Survival at Months:

ER/PR+ and HER2+ Survival Rate:

HER2+ only Survival Rate:

ER/PR+ only Survival Rate:

TNBC Survival Rate:


Gong Y, Liu Y-R, Ji P, Hu X, Shao Z-M. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Scientific Reports. 2017;7:45411. doi:10.1038/srep45411.